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ABSTRACT
A growing body of studies highlights involvement of neutrophils in cancer 
development and progression. Our aim was to assess the phenotypic and functional 
properties of circulating neutrophils from patients with chronic lymphocytic leukemia 
(CLL). The percentage of CD54+ and CD64+ neutrophils as well as CD54 expression 
on these cells were higher in CLL patients than in age-matched healthy controls. 
Neutrophils from CLL produced more reactive oxygen species (ROS) compared 
to controls in both resting and activated conditions. Lipopolysaccharide-induced 
production of IL-1β and TNF-a as well as reduced TLR2 expression in neutrophils 
from CLL than in neutrophils from controls suggesting their tolerant state. Finally, 
phenotypic alterations of neutrophils, particularly elevation of CD64 and CD54 markers, 
correlated with disease activity and treatment, and low percentage of neutrophils. 
Taken together, the alterations in percentage and functional characteristics of 
neutrophils reflect the clinical course of CLL. Our data provide first evidence that 
neutrophils in CLL are permanently primed and have functional defects.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is 
characterized by an accumulation of abnormal B 
lymphocytes in the bone marrow, lymphoid tissues and 
peripheral blood. The expansion of malignant clone(s) 
may in turn lead to phenotypic alterations of residual 
hematopoietic bone marrow cells such as those maturing 
neutrophils, monocytic and/or erythroid cells as well 
as CD34+ myeloid precursors; and this may be also 
reflected in circulating cells as shown already in myeloid 
malignancies [1, 2]. Whether such phenotypic alterations 
are also present in circulating neutrophils in CLL patients 
remains to be investigated.
Polymorphonuclear neutrophils are the most 
abundant phagocytes in the circulation and are 
traditionally associated with innate defense against 
infection [3, 4]. When activated, they release a spectrum of 
inflammatory mediators, produce reactive oxygen species 
(ROS), activate complement and regulate inflammation 
[5]. Besides, neutrophils mediate antibody-dependent 
cell-mediated cytotoxicity (ADCC) [6, 7]. A growing 
body of studies shows that their inappropriate activation 
is associated with inflammatory, autoimmune processes as 
well as cancer development and progression [8]. 
The circulating neutrophils from CLL patients 
were shown to possess impaired bactericidal activity [9], 
probably due to myeloperoxidase deficiency and impaired 
migratory abilities [10]. More recently, neutrophils were 
shown to differentiate toward a B-cell helper phenotype 
in murine model of CLL contributing to the formation 
of survival niches for CLL cells in lymph nodes [11]. 
Nevertheless, neutrophils in CLL may contribute to 
treatment response as shown by phagocytosis of about 
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50% of anti-CD20 (obinutuzumab, but not rituximab) 
opsonized CLL targets by drug-activated neutrophils [12].
In an attempt to further understand how neutrophils 
may contribute to CLL pathogenesis, we aimed to assess 
the phenotypic and functional properties of circulating 
neutrophils from patients with CLL. We investigated 
expression profiles of major membrane-bound markers 
associated with cell activation: i) surface adhesion 
molecules associated with inflammation (CD11b, CD62L, 
CD54), and ii) Fcγ receptor: FcγRI (CD64) using flow 
cytometry. Further, we determined the priming ability as 
well as baseline and stimulated generation of ROS by the 
neutrophils obtained from CLL patients.
RESULTS
Surface molecule expression on neutrophils
In order to characterize the circulating neutrophils 
in CLL, we investigated their immunophenotypes using 
following surface molecules CD54, CD11b, CD62L, and 
CD64 and compared with those on neutrophils from age-
matched healthy subjects. Neutrophils were selected in the 
forward versus side scatter dot plot, and additionally gated 
as CD15/CD16 positive cells (Supplementary Figure 1 in 
the on-line Supplement).
Figure 1: Distribution of percentage of surface markers (CD64, CD54, CD62L, CD11b) on circulating neutrophils 
from healthy controls and patients with CLL. Group means are indicated by horizontal bars, error bars indicate 95%CI; P values 
for differences between two groups are stated. 
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Expression of marker CD54 was increased (P 
< 0.001) and higher percentage (P < 0.01) of CD54+ 
neutrophils was observed in CLL patients compared to 
healthy controls (Table 1, Figure 1, Supplementary Figure 
2 in the on-line Supplement). When controls and CLL 
were compared, the percentage of CD64+ cells was 4-fold 
higher (P < 0.001) in CLL patients showing marked inter-
individual variability ranging from 1.2 to 93.3%. The 
expression (MFI) of CD64 did not differ between CLL 
vs controls (P = 0.71). Lower percentage of CD62L+ 
cells (P < 0.001) as well as lower expression of CD62L 
(P = 0.02) was found in neutrophils from CLL patients 
comparing to age-matched healthy controls (Table 1, 
Figure 1, Supplementary Figure 2 in on-line Supplement). 
Expression of CD11b on neutrophils did not vary between 
CLL patients and controls (P > 0.05). The comparison of 
expression of studied surface markers on neutrophils from 
healthy subjects and CLL patient subgroups according to 
the treatment history is shown in Supplementary Table 1 
in on-line Supplement.
Baseline expression of cell surface molecules on 
neutrophils in CLL subgroups
To determine whether disease activity, treatment, 
IGHV mutational status, Binet stage, blood number counts, 
and percentage of CLL cells affect the expression level 
of investigated markers on neutrophils, we compared 
the expression of CD54, CD11b, CD62L, and CD64 in 
CLL subgroups. Active disease was associated with 
upregulated expression of CD54 and CD64 (P < 0.01 and 
P < 0.01, respectively), increased percentage of CD64 
(P < 0.01) and downregulated expression (P < 0.05) 
and percentage (P < 0.01) of CD62L (Figure 2A, Figure 
3A, Supplementary Figure 3 in on-line Supplement). 
Treated CLL patients displayed simultaneously increased 
expression of CD64 (P < 0.001), higher percentage 
of CD64 (P < 0.05) and CD54 (P < 0.01) compared to 
untreated patients. Remarkable differences were observed 
for the percentage of CD64 cells, which were almost 4-fold 
higher in treated vs untreated patients (Figure 2B, Figure 
3B, Supplementary Figure 3 in on-line Supplement). 
Figure 2: Distribution of CD64, CD54 and CD62L positive neutrophils in CLL subgroups: A. non-active vs active disease, 
B. untreated vs treated disease, C. mutated vs unmutated IGHV gene status, D. CLL patients without infection vs with ongoing infection. 
Group means are indicated by horizontal bars, error bars indicate 95%CI; P values for differences between two groups are stated.
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When patient subgroups were compared according to 
Binet stage, the percentage of CD64+ cells was lower in 
patients with Binet stage A comparing to stages B and 
C (P < 0.05) (data not shown). In patients with ongoing 
infection, lower percentage of CD11b+, CD62L+ cells and 
expression of CD62L were detected comparing to those 
with no infection (Figure 2D, Supplementary Figure 3 in 
on-line supplement). Patients with unmutated IGHV gene 
status had decreased percentage of CD62L (P < 0.001) 
and a decreased MFI of CD62L (P < 0.05) compared with 
mutated IGHV status (Figure 2C, Supplementary Figure 3 
in on-line Supplement).
In our study, the percentage of circulating 
neutrophils in CLL showed a negative correlation with 
CD64 percentage and MFI (r = 0.45, P < 0.01 and r = 0.24, 
P = 0.07, respectively) and CD54 percentage and MFI (r 
= 0.34, P < 0.05 and r = 0.43, P < 0.01, respectively). In 
opposite, neutrophil percentage positively correlated with 
CD62L (%) and MFI (r = 0.41, P < 0.01 and r = 0.46, P 
< 0.01, respectively) (Supplementary Figure 4 in on-line 
Supplement). 
Figure 3: Percentage of circulating neutrophils and surface markers (CD64, CD54, CD62L, CD11b) in CLL subgroups. 
Comparison of studied parameters (medians) between A. non-active (light red columns) vs active (dark red columns) disease, B. untreated 
(light blue columns) vs treated (dark blue columns) disease, C. mutated (light violet columns) vs unmutated (dark violet columns) IGHV 
gene status. The arrows indicate the increase/decrease in studied parameters in non-active/untreated/mutated CLL subgroups compared to 
active/treated/unmutated subgroups, respectively.
Oncotarget84893www.impactjournals.com/oncotarget
Cellular pattern of peripheral blood in CLL 
patients
Further, we compared percentage of circulating 
neutrophils, lymphocytes and CLL cells (as assessed 
by CD5+/CD19+) in patient subgroups according to 
the disease activity, treatment history and IGHV gene 
mutational status. Majority of enrolled CLL patients had 
decreased percentage of circulating neutrophils compared 
to healthy subjects (Table 1). The absolute number of 
neutrophils in CLL patients did not differ from those in 
healthy controls (Table 1), only 3 patients had absolute 
neutropenia ( < 2.0 x 109/L). Active disease was associated 
with a increased of neutrophil percentage (P < 0.001) 
and increased percentage of lymphocytes (P < 0.01) and 
CLL cells (P < 0.01) comparing to non-active disease. 
Patients with unmutated IGHV gene status had lower 
percentage of neutrophils than those with mutated IGHV 
(P < 0.05), the difference in neutrophils between treated 
and untreated patients did not reach significance (Table 1, 
Supplementary Figure 5 in the on-line Supplement).
Characteristics of neutrophils associated with 
CLL and its subgroups
To better characterize the neutrophils in CLL, 
we determined which markers discriminate i) CLL and 
healthy controls and ii) CLL subgroups according to 
the disease activity, treatment history and IGHV gene 
mutational status. We calculated combinations of every 
two and three markers (percentage and MFI of studied 
surface markers, percentages of neutrophils, lymphocytes 
and CLL cells) from individual patients and determined 
the misclassification error for a particular subgroup. 
Figure 4: Comparison of percentage of circulating neutrophils and surface markers (CD64, CD54, CD62L, CD11b) in 
CLL patients and healthy controls. CLL is coloured yellow, control subjects green. Discrimination between CLL and controls using 
combination of two parameters: A. CD54 (%) - neutrophils (%) and B. CD64 (%) - neutrophils (%). The dots represent the percentage of 
CD54/CD64 (y-axis) and neutrophils (x-axis) in individual subjects. C. Comparison of studied parameters (medians) between CLL (yellow 
columns) and healthy groups (green columns). The arrows indicate the increase/decrease in studied parameters in CLL patients compared 
to healthy controls.
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Table 1: Relative and absolute neutrophil counts and expression levels of surface markers on neutrophils in: A. healthy 
controls vs CLL, B. non-active CLL vs active CLL, C. untreated CLL vs treated CLL, D. mutated IGHV gene status 
vs unmutated IGHV gene status.
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The best separation of healthy controls and CLL 
using two markers was achieved for combination of CD64 
(%) - neutrophil (%) and CD54 (%) - neutrophil (%), thus 
further confirming observation that lower percentage of 
neutrophils is associated with higher percentage of CD64 
and CD54 markers (Figure 4). Similarly, combination 
of CD64 (%) - CD54 (%) - neutrophil (%) showed good 
separation between studied CLL subgroups, achieving a 
classification error less than 15 % (Figure 5).
Figure 5: Multidimensional clustering of CLL subgroups. Discriminant 3-D models with combination of CD64 (%) - CD54 (%) 
- neutrophils (%) show the separation of following CLL subgroups: A. non-active (light red clouds) vs active (dark red clouds) disease, B. 
untreated (light blue clouds) vs treated (dark blue clouds) disease, C. mutated (light violet clouds) vs unmutated (dark violet clouds) IGHV 
gene status. The dots represent the percentage of CD54 (x-axis), CD64 (y-axis) and neutrophils (z-axis) of individual subjects. The colour 
bulks represent the probability intervals: the more saturated color the higher probability (intervals: > 90, 90-80, 80-70, 70-60, and 60-50%) 
of correct classification. 
ANC: Absolute neutrophil count. The normal range for the ANC = 1.5 to 8.0x109/L.
#FC (Fold Change) between group medians
*CD54 available in 39 patients and 34 controls
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Influence of fMLP and PMA on ROS production 
by neutrophils
Having identified increased expression of pro-
inflammatory surface antigens by neutrophils from the 
patients, we next sought to investigate the basal and 
induced ROS generation in neutrophils ex vivo. For this 
purpose, we induced whole blood cells with fMLP (weak 
chemotactic stimulus) and PMA (non-receptor-dependent 
activator of protein kinase C) and measured conversion of 
DHR-123.
The fraction of neutrophils with spontaneous 
(resting burst) ROS production was increased in patients 
with CLL compared to controls (mean MFI; 34.9 vs 
24.2, P < 0.05). The average increase in ROS response 
to fMLP was detected in CLL group compared to basal 
secretion level (42.4 vs 34.9, P < 0.01) and compared to 
healthy control group (42.4 vs 28.7, P < 0.05). Despite 
PMA markedly induced ROS production by neutrophils 
in both healthy and CLL groups (P < 0.01 and P < 0.001, 
respectively), stimulation with PMA has led to a maximum 
ROS-release in neutrophils from CLL patients that was 
4-fold greater than those in healthy controls (1125 vs 281, 
P < 0.01) (Figure 6A).
Surface marker expression on neutrophils after 
LPS priming
To determine whether the observed phenotypical 
changes of neutrophils in CLL are associated with altered 
functional responses of the cells, we primed circulating 
neutrophils with LPS and measured expression levels of 
CD54, CD11b, CD62L, CD64, TLR2 and TLR4 using 
flow cytometry. Phenotypic changes induced by LPS ex 
vivo were selective. LPS upregulated expression of CD11b 
and TLR2 in healthy cells, and CD11b in CLL group (P 
< 0.05). In opposite, TLR2 expression after LPS exposure 
was downregulated in neutrophils from CLL patients 
(Supplementary Figure 6 in on-line Supplement). The 
expression of other markers was not influenced by LPS 
exposure (P > 0.05).
Table 2: Patient characteristics.
*For more information regarding the treatment in previously treated CLL patients see Supplementary Table 2 in on-line 
Supplement.
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IL-1β and TNF-a production in cell culture 
supernatants after LPS priming and TNF-a levels 
in serum
We further studied the impact of bacterial LPS on 
IL-1β and TNF-a release by cultured neutrophils from 
patients with CLL and healthy subjects. Additionally, we 
investigated the protein levels of TNF-a in sera of CLL 
patients and healthy controls. 
LPS stimulation of isolated neutrophils from control 
group induced production of both pro-inflammatory 
cytokines (P < 0.05). In contrast, neutrophils from CLL 
patients failed to induce either IL-1β or TNF-a release 
from LPS-stimulated cells. Moreover, LPS exposure 
decreased production of IL-1β by neutrophils isolated 
from CLL patients (P < 0.05). Both LPS-induced 
production of IL-1β and TNF-a in CLL group was lower 
than those released by neutrophils from healthy group (P 
< 0.05) (Figure 6B, 6C). 
When comparing the serum levels of TNF-a, higher 
serum level was observed in CLL patients than in healthy 
controls (P < 0.001) (Supplementary Figure 7 in on-line 
Supplement).
DISCUSSION
A growing body of evidences emphasizes the 
importance of the complex relationship between the CLL 
clone(s) and its immune environment. The contribution 
of neutrophils, effectors in both innate and adaptive 
immunoregulatory networks, to the pathogenesis of CLL 
was not established yet. To gain more insights on the 
phenotype of circulating neutrophils in CLL, we studied 
expression of membrane-bound markers associated with 
cell activation (CD54, CD11b, CD62L, CD64). Our data 
demonstrates for the first time that patients with CLL have 
increased percentages of circulating  CD54+ and CD64+ 
neutrophils and increased CD54 expression. It is tempting 
to speculate that activated phenotype of neutrophils in 
CLL, irrespective of infection, is a result of the presence 
of systemic inflammatory cytokine milieu [13, 14] 
which largely promotes pro-survival and proliferation 
signaling in tumor cells [15]. Our data on increased serum 
concentrations of TNF-a provide further support for the 
concept of a systemic inflammation in CLL. 
Importantly, we detected an increase in the ROS-
generating activity in neutrophils from CLL patients 
suggesting their functionality. CLL patient neutrophils 
produced markedly more ROS in both resting condition 
as well as after stimulation with fMLP and PMA ex 
vivo than healthy neutrophils. The increased oxidative 
potential of these cells could be explained by their altered 
energy metabolism or chronic activation of the immune 
system, thus deserving further investigations. Generally 
circulating neutrophils are a major source of ROS in 
human blood, having main involvement in microbial 
defense. While keeping the same absolute number of 
circulating neutrophils in CLL as in healthy controls, 
the contribution of increased ROS-generating activity in 
neutrophils from CLL patients may have significant effects 
on the pathophysiology of CLL far beyond these cells. In 
line with our observation, there is already evidence about 
a robust extracellular release of ROS from neutrophils in 
CLL exposed to anti-CD20 treatment or αCD20-opsonized 
CLL cells [16]. The same authors proved that the enhanced 
ROS production by neutrophils and monocytes in CLL 
may limit the NK cell-mediated ADCC against CLL cells 
during anti-CD20 treatment, as NK cell ADCC could be 
partially restored by anti-oxidative agents [17]. Enhanced 
ROS production from neutrophils may also participate in 
tumorigenesis [18], induce mutations and genotoxicity 
generally [19], contribute to drug resistance and 
aggressive disease course [20] as well as to a systemic T- 
and NK-cell dysfunction [21]. More studies are warranted 
to investigate whether ROS released from activated 
Figure 6: Functional analyses of circulating neutrophils. A. Basal (rest) and fMLP- and PMA-induced ROS production by 
neutrophils from the blood of CLL patients (CLL, n = 18) and healthy controls (control, n = 17). Error bars represent means ± SEM. Induced 
(*P < 0.05, **P < 0.01, ***P < 0.001) vs resting ROS production; (#P < 0.05, ##P < 0.01) in CLL vs control group. B. IL-1β and C.TNF-a 
release by neutrophils isolated from the blood of CLL patients (CLL, n = 16) and healthy controls (control, n = 7) after priming with LPS. 
Error bars are means ± SEM (*P < 0.05, **P < 0.01) vs media; (#P < 0.05, ##P < 0.01) vs control group.
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neutrophils may prevent effective elimination of CLL cells 
during treatment and contribute to the disease progression 
as well as perspectives of anti-oxidative drugs to restore 
the effector function of NK cells in treated patients.
Next, we were interested whether immunophenotype 
of neutrophils in CLL changes during the disease 
course. Indeed, significant differences in phenotypic 
characteristics of neutrophils have been found in our 
patients with active disease, treatment histories as well as 
unmutated IGHV gene status, mainly by elevation of CD64 
and CD54 expression. Of note, upregulation of CD64 and 
CD54 was associated with low absolute number and low 
percentage of circulating neutrophils as well as high CLL 
cells/neutrophils ratio, but not linked to ongoing infection. 
CD64 (Fcγ receptor I) is expressed by neutrophils when 
they are activated [22] and serves therefore as a marker for 
the systemic inflammation and infections [23]. In addition 
to promoting phagocytosis, CD64 mediates cytotoxicity 
and activates oxidative burst [24]. CD64 is upregulated 
in many inflammatory diseases as well as solid tumor cell 
lines [25]. It has been shown that CD64 expression is also 
induced by IFNγ [26], a cytokine relevant for development 
and/or progression of CLL [27]. We therefore suggest 
that the pro-inflammatory cytokine environment in CLL 
certainly contributes to the elevation of CD64. So far, 
several lines of evidence indicate that elimination of 
CD64-positive macrophages and neutrophils resolves 
chronic inflammation thus suggesting that this marker 
may regulate chronicity of inflammation [28, 29]. Taken 
together, the results of the present study suggest that 
immunophenotype of neutrophils and particularly CD64 
expression is affected by more aggressive disease course. 
The harm effect of CD64 in CLL, and its relevance to the 
altered function of circulating neutrophils bearing this 
receptor remain elusive.
Modulation of neutrophil activation state is 
accomplished by a number of mechanisms, including 
neutrophil priming. In this study, the response to bacterial 
endotoxin was markedly attenuated in the patients’ 
neutrophils. LPS exposure of neutrophils in CLL has led 
to the decreased release of two main pro-inflammatory 
cytokines, IL-1β and TNF-a, comparing to neutrophils 
from healthy controls. Flow cytometry revealed that 
LPS priming caused selective downregulation of TLR2 
on the surface of neutrophils from CLL patients without 
influencing the expression of other studied molecules. 
Thus, neutrophils in CLL failed to mount a standard 
inflammatory response and exhibited unusual activated 
immunophenotype with characteristics of suppressed 
functionality. Such abnormal state of neutrophils might be 
defined as a tolerance of neutrophils to endotoxin which 
represents adaptive response of organism that protects 
against exaggerated inflammation. Persistent inflammation 
leads to dysfunction of innate immune responses and as 
a result increased susceptibility to infections. Failure 
to raise a proper inflammatory reaction might be vital 
for the antimicrobial defense in patients with CLL and 
compromise the ability to kill microbial invaders. This is 
in line with an emerging concept that monocytes in CLL 
exert primary features of endotoxin tolerance [30, 31]. 
Similar refractory behaviour, known as ‘tumor tolerance’, 
has been described in tumor-associated macrophages after 
repeated contacts with cancer cells [32, 33]. Whether 
observed functionality on neutrophils is a result of 
persistent presence of neoplastic cells or ‘real’ endotoxin 
tolerance is unknown. Further studies are needed to clarify 
this issue.
In conclusion, our data provide first evidence that 
neutrophils in CLL are permanently primed and have 
functional defects. Their phenotype reflects clinical course 
of the disease and may account for higher susceptibility to 
bacterial infection in active and treated CLL. The precise 
mechanisms by which neutrophils contribute to CLL 
pathogenesis remain unclear and further investigations 
of neutrophil functions in the context of leukemia and 
leukemia-related inflammation are needed.
MATERIALS AND METHODS
Study population and materials
We analyzed peripheral blood samples from 54 
patients with CLL, all diagnosed according to the IWCLL 
guidelines [34]. Subgroups were formed based on disease 
activity (sign of progressive/symptomatic disease as 
defined in the IWCLL guidelines) [34], treatment history 
and IGHV mutational status. Ongoing infections were 
clinically and laboratory (CRP serum levels, procalcitonin 
levels, etc.) documented. All previously treated CLL 
patients were not receiving any treatment during the 
previous 17 (median, range 1-63) months before sampling; 
none of the patients received therapy at the time of the 
blood analysis. For more details about the used treatment 
in enrolled CLL patients and time between last treatment 
and the sampling see Supplementary Table 2 in on-line 
supplement. The clinical characteristic of CLL patients is 
shown in Table 2.
Peripheral blood samples from 37 healthy age-
matched control subjects (median age 68 yrs; range 38-90 
yrs) were taken from members of medical staff or their 
relatives; all completed a questionnaire regarding their 
health status. Peripheral blood samples from patients and 
controls were processed within an hour after collection. 
Serum samples were aliquoted and stored at -80°C until 
analysis. All patients and controls provided written 
informed consent about the usage of peripheral blood 
for the purpose of this study. The study was approved by 
the ethics committee of University Hospital and Palacky 
University Olomouc.
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Neutrophil surface receptor expression measured 
by flow cytometry
Neutrophils in whole blood were stained with 
antibodies to the various surface molecules by a direct 
immunofluorescence technique. To avoid the aberrant 
sedimentation of granulocytes evident in cancer patients 
causing the loss of neutrophils during isolation procedure 
[21], we analyzed neutrophils in whole blood. Viability of 
neutrophils, assessed by trypan blue exclusion and flow 
cytometry of propidium iodide-stained cells, was greater 
than 98%. Briefly, optimal concentrations of monoclonal 
antibody combinations directed against the following 
human surface antigens: anti-CD54-FITC (clone HA58), 
anti-CD11b-PerCP-Cy5.5 (clone ICRF44), anti-CD15-
Pe-Cy7 (clone W6D3), anti-CD62L-APC (clone DREG-
56), anti-CD64-APC-Cy7 (clone 10.1) (all BioLegend) 
and anti-CD16-PE (clone B-E16, IQ Products) were 
incubated with 50 μL of whole blood for 20 minutes at 
room temperature in the dark. This was followed by lysis 
of the red blood cells with 2 mL of FACS lysing solution 
(diluted 1:10 with distilled water; Becton Dickinson) and 
washing with PBS containing 1% bovine serum albumin 
(BSA). Neutrophils were identified by their light scatter 
characteristics and bright immunofluorescence with anti-
CD15 and anti-CD16 mAb (Supplementary Figure S1 in 
on-line supplement). Isotype matched FITC, PE, PerCP-
Cy5.5, Pe-Cy7, APC and APC-Cy-7-conjugated irrelevant 
antibodies (all clones MOPC-21, BioLegend) were used 
as negative controls. Analysis was performed on a BD 
FACSCanto II (Becton Dickinson). Data acquisition 
was performed using BD FACSDiva software (Becton 
Dickinson). Flow cytometry data were analyzed using 
the FlowJo vX0.7 software (Tree Star, Inc, San Carlos, 
CA). In all experiments, a minimum of 10,000 events was 
counted. Results are expressed as the percentage and MFI 
of the cells for each examined marker.
Oxidative burst assay
Neutrophil oxidative stress capacity was analyzed 
using dihydrorhodamine 123 (DHR-123) (Sigma-
Aldrich), a nonfluorescent compound which accumulates 
in mitochondria and is converted to the highly fluorescent 
rhodamine-123 by the action of oxidative stress. Briefly, 
the tubes with whole blood were prelabeled with CD15 
and incubated with 20 μM DHR-123 (stock solution 
5.7 mM DHR-123 in dimethyl sulphoxide, DMSO) in 
the dark at 37°C for 20 minutes. Then either 400 nM 
N-Formyl-Met-Leu-Phe (fMLP, Sigma-Aldrich, 11.4 mM 
stock solution in DMSO) or 2 μM Phorbol 12-myristate 
13-acetate (PMA, Sigma-Aldrich, 1.6 mM stock solution 
in DMSO) was added and the cell suspensions were 
incubated in the dark at 37°C for further 20 minutes. For 
the negative control, whole blood cells were incubated 
with DMSO. The red blood cells were lysed with FACS 
lysing solution. 
Isolation of peripheral blood neutrophils and 
priming with LPS
Peripheral blood samples were collected in 
tubes containing EDTA and processed within an hour 
after collection. Neutrophils were isolated by density 
centrifugation using the Histopaque gradient technique 
(Sigma-Aldrich) according to the manufacturer’s protocol. 
Contaminating erythrocytes were removed with FACS 
lysing solution and washed with PBS containing 1% 
BSA. Viability of neutrophils after purification, assessed 
by trypan blue exclusion and flow cytometry of propidium 
iodide-stained cells, was greater than 96%.
For priming of isolated neutrophils, cells (1.5 × 106 
cells/mL) were cultured at 37°C in RPMI-1640 (Sigma-
Aldrich) supplemented with 10% heat-inactivated fetal 
calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 
5 mM HEPES, 100 U/mL of penicillin, 100 µg/mL of 
streptomycin in the absence or presence of 100 ng/mL 
LPS (Escherichia coli 0111:B4, Sigma-Aldrich) in a 
total volume of 500 µL for 4 hours. After stimulation, 
neutrophils were harvested, washed once with cold PBS 
and stained with anti-CD54, CD64, CD11b, CD15, TLR2 
(clone TL2.1), TLR4 (clone HTA125) (all BioLegend) and 
analyzed with flow cytometer similarly to the analysis of 
surface antigens. Supernatants were stored at -80°C until 
analysis of cytokine production.
ELISA in supernatants and serum
Enzyme-linked immunosorbent assay (ELISA) 
kits were used to measure the levels of IL-1β and TNF-a 
(BioLegend) in cell-culture supernatants; Human TNF-a 
Quantikine HS ELISA (R&D Systems, Inc.) for the levels 
of TNF-a in serum. The assays were performed following 
the manufacturer’s recommendations and absolute 
cytokine levels were calculated based on comparison to 
assay performance in the presence of known quantities 
of recombinant cytokine standards. The detection limits 
of ELISA were 0.5 and 2 pg/mL for IL-1β and TNF-a 
(BioLegend), and 0.19 pg/mL for TNF-a (R&D Systems, 
Inc), respectively.
Statistical analyses
Statistical analyses were performed using GraphPad 
Prism 5·0 (GraphPad Software, La Jolla, CA, USA) and 
R statistical software package (http://www.r-project.
org/). Subsequently, the Mann-Whitney U-test was used 
to compare the expression of markers between groups. 
Differences between unstimulated and stimulated samples 
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from the same subject were calculated using the Wilcoxon 
non-parametric test for paired samples. P values < 0.05 
were considered significant. Multilinear Discriminant 
Analysis (MDA) and extended Support Vector Machine 
(kSVM) [35] were used to calculate the class probabilities 
for combinations of two/three markers using R statistical 
software with package Caret (http://topepo.github.io/caret/
index.html).
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